Showing 6741-6750 of 10580 results for "".
- AAD: Half of Americans Aren't Protecting Themselves from the Sunhttps://practicaldermatology.com/news/aad-half-of-americans-arent-protecting-themselves-from-the-sun/2460018/Most Americans aren’t using sun protection as often as they should be —increasing their risk for skin cancer, including melanoma. In fact, just half of Americans always or almost always protect themselves from the sun when they’re outside, according to a new survey by
- Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for NMSC Patients Treated with Superficial Radiation Therapyhttps://practicaldermatology.com/news/five-year-retrospective-study-shows-989-percent-cure-rate-for-nmsc-patients-treated-with-superficial-radiation-therapy/2460013/Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma ski
- SkinBioTherapeutics Names New Executive Directorhttps://practicaldermatology.com/news/skinbiotherapeutics-names-new-executive-director/2460012/Stuart Ashman is the new executive director of SkinBioTherapeutics. Mr. Ashman will succeed Professor Cath O’Neill as CEO after a period of transition. Ms. O’Neill will continue to drive the science and the ongoing commercial
- Study Highlights Adverse Events Associated with Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/study-highlights-adverse-events-associated-with-energy-based-vaginal-rejuvenation/2460010/Concerns from the federal Food and Drug Administration (FDA) sired the first assessment of adverse events related to device-based procedures marketed for ‘vaginal rejuvenation,’ and the new analysis of the Manufacturer and User Facility Device Experience (MAUDE) database identified a
- FDA Approves AbbVie's Skyrizi for Psoriasishttps://practicaldermatology.com/news/fda-approves-abbvies-skyrizi-for-psoriasis/2460007/Skyrizi™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical trials, Skyrizi prod
- L'Oreal To Support Reconstruction of Notre Dame Cathedralhttps://practicaldermatology.com/news/loreal-to-support-reconstruction-of-notre-dame-cathedral/2460003/The Bettencourt Meyers family and the L’Oréal Group are making a joint donation of 100 million euros toward the “renaissance” of the Notre-Dame Cathedral, which they describe as a symbol of French heritage and common history.
- Industry Vet Linda Esposito Named New CFO at Skyn ICELANDhttps://practicaldermatology.com/news/industry-vet-linda-esposito-named-new-cfo-at-skyn-iceland/2460002/Linda Esposito is the new Chief Financial Officer at Skyn ICELAND, a privately held New York-based skin care company. Ms. Esposito will report to Founder and Chief Executive Officer Sarah Kugelman and will oversee all financial aspects of t
- American Skin Association Names Almirall Distinguished Corporate Leaderhttps://practicaldermatology.com/news/american-skin-association-names-almirall-distinguished-corporate-leader/2459997/Almirall took home the Distinguished Corporate Leadership award by the American Skin Associ
- Allergan 360° Aesthetics Report Shines Light on Evolving Beauty Perceptions Around the Worldhttps://practicaldermatology.com/news/allergan-3600-aesthetics-report-shines-light-on-evolving-beauty-perceptions-around-the-world/2459994/The digital boom and millennials are growing the aesthetics category, and wellness and self-care are the new key drivers, according to the Allergan 360° Aesthetics Report. To develop the report, Allergan tapped into more than 14,500
- Derm Students Improve Wikipedia Entries on Skin Disease, Boost Viewshttps://practicaldermatology.com/news/derm-students-improve-wikipedia-entries-on-skin-disease-boost-views-1/2459992/A group of medical students recruited to improve Wikipedia articles on skin-related diseases and saw millions more views of those stories following their editing, a new study shows. "We tried to make the articles more readable, while adding more relevant information," say